10-Q: Synergy Empire Limited: Q3 2025 Results & Strategic Shift

Synergy Empire Limited reports Q3 2025 results, detailing a strategic pivot to biopharmaceutical contract manufacturing following the acquisition of Meluha Therapeutics Berhad.

Summary

• Synergy Empire Limited filed its Form 10-Q for the quarterly period ended December 31, 2024.
• The company reported a net loss of $35,234 for the three months ended December 31, 2024, compared to a net loss of $3,944 for the same period in 2023.
• For the nine months ended December 31, 2024, the net loss was $63,719, compared to $74,261 for the same period in 2023.
• Revenue for the nine months ended December 31, 2024, was $15,000 from consultancy services, a shift from the previous asset leasing business which was discontinued.
• The company disposed of its Malaysian subsidiaries (Lucky Star and SH Dessert) on January 1, 2024, discontinuing its asset leasing business.
• A significant event was the acquisition of Meluha Therapeutics Berhad, a biopharmaceutical company, through a stock purchase agreement executed on July 29, 2024, and consummated on March 28, 2025.
• This acquisition represents a reverse takeover, shifting Synergy Empire Limited's business focus to biopharmaceutical contract manufacturing and R&D.
• The company has accumulated deficits of $1,022,598 as of December 31, 2024, and negative working capital, raising substantial doubt about its ability to continue as a going concern.
• The company is implementing measures to address material weaknesses in internal controls, including adding staff and enhancing accounting expertise.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to continued net losses, significant accumulated deficits, negative working capital, and material weaknesses in internal controls, despite the strategic pivot to a new industry.

Positives

• Strategic pivot to the biopharmaceutical sector through the acquisition of Meluha Therapeutics Berhad, a growing industry.
• The acquisition of Meluha Therapeutics Berhad, if successful, could provide a new growth avenue and potentially improve financial performance.
• The company has identified and is initiating remediation steps for material weaknesses in its internal controls.

Negatives

• Significant net losses continue, with a loss of $35,234 for the three months and $63,719 for the nine months ended December 31, 2024.
• Accumulated deficit of $1,022,598 as of December 31, 2024.
• Negative working capital of $370,598 as of December 31, 2024, indicating potential liquidity issues.
• Substantial doubt about the company's ability to continue as a going concern.
• Material weaknesses identified in internal controls over financial reporting, including lack of segregation of duties and insufficient competent personnel.
• Increase in general and administrative expenses due to write-off of bad debts, indicating collection issues.

Risks

• The company's ability to continue as a going concern is dependent on improving profitability and securing financial support, with uncertainty regarding future funding.
• The success of the reverse takeover and integration of Meluha Therapeutics Berhad is critical for the new business direction.
• Material weaknesses in internal controls could lead to misstatements in financial reporting and potential fraud.
• Reliance on a single customer for 100% of revenue in the consultancy business presents a significant concentration risk.
• The company's shift to the biopharmaceutical sector involves inherent risks associated with research and development, regulatory approvals, and market competition.

Future Outlook

The company's future outlook is heavily dependent on the successful integration and performance of Meluha Therapeutics Berhad, its new biopharmaceutical business. The company acknowledges the need for additional funding and is working to improve profitability and operational efficiency to address going concern uncertainties. Remediation of internal control weaknesses is also a key focus.

Management Comments

• The board believes that the disposal of these subsidiaries would help reduce the Company's ongoing accumulated deficits, leading to more efficient operations in the long term.
• With the divestment, the Company decided to shift its focus to providing consultancy services to restaurant owners, specializing in restaurant and kitchen management. This strategic move leverages the Directors extensive experience in the food and beverage industry.
• Management believes it is more likely than not that the deferred tax assets will not be fully realizable in the future.
• Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company's financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company's business, financial position, and results of operations or cash flows.

Industry Context

StockSavvy.ai notes that Synergy Empire Limited's strategic shift into the biopharmaceutical contract manufacturing sector via a reverse takeover is a significant move, aligning with the broader trend of companies seeking growth in specialized, high-potential industries. The biopharmaceutical sector is characterized by substantial R&D investment, stringent regulatory environments, and significant market opportunities, particularly in contract manufacturing as companies outsource production.

Comparison to Industry Standards

• The company's financial performance, characterized by net losses and accumulated deficits, is not comparable to established, profitable biopharmaceutical companies. For instance, major contract manufacturers in the biopharmaceutical space like Lonza Group or Catalent typically report significant revenues and profits, reflecting their scale and market position.
• Synergy Empire Limited's current revenue of $15,000 for nine months is substantially lower than industry benchmarks for companies operating in the biopharmaceutical contract manufacturing sector, which often generate hundreds of millions or billions in revenue.
• The company's focus on addressing material weaknesses in internal controls is a critical step towards meeting the robust governance and reporting standards expected in the public markets, especially for companies in regulated industries like biopharmaceuticals.

Corporate Governance

Legal Proceedings

• The company is not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on its business, prospects, financial condition, or results of operations.

Related Party Transactions

• Amount due to director Hsien Loong Wong: $62,745 as of December 31, 2024.
• Amount due to shareholder Michael Tan (assigned from previous director Will Liam Leong): $289,026 as of December 31, 2024.
• The consultancy services are provided by the sole director, Mr. Hsien Loong Wong, without remuneration.

Stakeholder Impact

• Shareholders: Continued losses and going concern uncertainties may negatively impact share value. The strategic shift to biopharmaceuticals could offer future growth potential but also carries significant risk.
• Creditors: The company's negative working capital and going concern issues may raise concerns for creditors regarding timely repayment of obligations.
• Employees: The company's financial instability and ongoing restructuring could create job insecurity. The shift to a new industry may require new skill sets.
• Management: Facing challenges in improving financial performance, addressing internal control weaknesses, and executing the new business strategy.

Next Steps

• Implement remediation initiatives to address material weaknesses in internal controls.
• Focus on improving profitability and securing financial support to address going concern uncertainties.
• Successfully integrate Meluha Therapeutics Berhad and develop its biopharmaceutical contract manufacturing business.
• Continue to monitor and manage financial condition and results of operations.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation with a reverse takeover into the biopharmaceutical sector, which presents both high potential and high risk. However, the continued net losses, substantial accumulated deficit, negative working capital, and identified material weaknesses in internal controls create significant uncertainty. While the new business direction is promising, the immediate financial health and control environment warrant a cautious 'hold' recommendation until performance and stability improve.

Keywords

Synergy Empire Limited, Form 10-Q, Quarterly Report, Meluha Therapeutics Berhad, Biopharmaceutical, Contract Manufacturing, Reverse Takeover, Financial Statements, Going Concern, Internal Controls, Consultancy Services, Nevada